Clinical Trials Directory

Trials / Completed

CompletedNCT01206309

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)

Status
Completed
Phase
Study type
Observational
Enrollment
911 (actual)
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

Detailed description

Allogeneic hematopoietic cell transplantation (HCT) is the only known curative option for many hematologic disorders. After transplantation, many patients develop immune mediated disorders that may be life-threatening such as graft versus host disease (GVHD). The morbidity and mortality associated with HCT-associated immune mediated disorders are major barriers to successful use of transplantation to cure rare hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myelodysplastic/myeloproliferative syndromes amongst other diseases. With this study, the investigators will investigate the biologic basis for immune mediated disorders after allogeneic HCT, focusing on those developing cutaneous sclerosis, bronchiolitis obliterans syndrome, late acute GVHD and chronic GVHD. The study will enroll 1118 (1018 adults and 100 children) allogeneic HCT patients over a three year period. Subjects will be followed for two years and monitored closely for development of immune mediated disorders. This study will have 5 study visits at day 1, 100, 180, 365, and 730. During these visits, a physical assessment, medication review, blood and urine collection will occur. If a subject develops an immune mediated disordered, they will be monitored at 3 months, 6 months, 1 year and then annually from the date of diagnosis. During these study visits, a physical assessment, IMD status, and medication review as well as blood and urine collection will occur.

Conditions

Timeline

Start date
2011-03-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2010-09-21
Last updated
2016-10-07

Locations

14 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01206309. Inclusion in this directory is not an endorsement.